Positron emission tomography of the vulnerable atherosclerotic plaque in man - a contemporary review

Clinical Physiology and Functional Imaging

Volumn 34, Issue 6, 2014, Pages 413-425

  Pedersen, Sune F ^a   Hag, Anne Mette F ^a   Klausen, Thomas L ^a   Ripa, Rasmus S ^a   Bodholdt, Rasmus P ^a   Kjær, Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Atherosclerosis; in vivo; Molecular imaging; Positron emission tomography; Vulnerable plaque

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM DOTATATE GA 68; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; SODIUM FLUORIDE F 18; VASCULAR CELL ADHESION MOLECULE 1; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL DIAMETER; CAROTID ATHEROSCLEROSIS; CYTOKINE RELEASE; DRUG UPTAKE; HYPOXIA; IMAGE QUALITY; IMAGE RECONSTRUCTION; MOLECULAR IMAGING; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; VASCULAR ENDOTHELIAL CELL; VASCULAR SMOOTH MUSCLE; ANIMAL; CAROTID ARTERY; CAROTID ENDARTERECTOMY; CAROTID STENOSIS; COMPLICATION; HUMAN; PATIENT SELECTION; PREDICTIVE VALUE; PROGNOSIS; RUPTURE; SCINTISCANNING; SEVERITY OF ILLNESS INDEX;

ANIMALS; CAROTID ARTERIES; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; HUMANS; PATIENT SELECTION; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RUPTURE, SPONTANEOUS; SEVERITY OF ILLNESS INDEX;

EID: 84907948508     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/cpf.12105     Document Type: Article

References (105)

1. Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, Brady TJ, Hoffmann U, Tawakol A. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT Study. Circ Cardiovasc Imaging (2013); 6: 747-754.
2. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer (2005); 92: 1493-1498.
3. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation (2007); 116: 2841-2850.
4. Aldrovandi A, Cademartiri F, Arduini D, Lina D, Ugo F, Maffei E, Menozzi A, Martini C, Palumbo A, Bontardelli F, Gherli T, Ruffini L, Ardissino D. Computed tomography coronary angiography in patients with acute myocardial infarction without significant coronary stenosis. Circulation (2012); 126: 3000-3007.
5. Armani C, Catalani E, Balbarini A, Bagnoli P, Cervia D. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol (2007); 81: 845-855.
6. Ashraf MZ, Gupta N. Scavenger receptors: implications in atherothrombotic disorders. Int J Biochem Cell Biol (2011); 43: 697-700.
7. Ballotta E, Angelini A, Mazzalai F, Piatto G, Toniato A, Baracchini C. Carotid endarterectomy for symptomatic low-grade carotid stenosis. J Vasc Surg (2013); doi: 10.1016/j.jvs.2013.06.079. [Epub ahead of print].
8. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med (2005); 46: 1333-1341.
9. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res (2006); 12: 3942-3949.
10. Ben-Haim S, Kupzov E, Tamir A, Frenkel A, Israel O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. J Nucl Cardiol (2006); 13: 791-800.
11. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R. A combined PET/CT scanner for clinical oncology. J Nucl Med (2000); 41: 1369-1379.
12. Bjornheden T, Levin M, Evaldsson M, Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol (1999); 19: 870-876.
13. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med (1962); 3: 332-334.
14. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68 Ga. Eur J Nucl Med Mol Imaging (2005); 32: 478-485.
15. Brix G, Lechel U, Glatting G, Ziegler SI, Munzing W, Muller SP, Beyer T. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med (2005); 46: 608-613.
16. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyogg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med (2010); 51: 401-412.
17. Burger C, Goerres G, Schoenes S, Buck A, Lonn AH, Von Schulthess GK. PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging (2002); 29: 922-927.
18. Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol (2012); 60: 1207-1216.
19. Chaturvedi S, Bruno A, Feasby T, Holloway R, Benavente O, Cohen SN, Cote R, Hess D, Saver J, Spence JD, Stern B, Wilterdink J. Carotid endarterectomy-an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2005); 65: 794-801.
20. Cherry SR, Dahlbom M PET: physics, instrumentation, and scanners. In: PET: Molecular Imaging and Its Biological Applications (ed. M Phelps ) (2004), pp. 1-125. New York: Springer-Verlag.
21. Czernin J, Benz MR, Allen-Auerbach MS. PET/CT imaging: the incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol (2010a); 73: 470-480.
22. Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med (2010b); 51: 1826-1829.
23. Dalm VA, Van Hagen PM, Van Koetsveld PM, Achilefu S, Houtsmuller AB, Pols DH, Van Der Lely AJ, Lamberts SW, Hofland LJ. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab (2003); 285: E344-E353.
24. Demer L, Tintut Y. The roles of lipid oxidation products and receptor activator of nuclear factor-kappaB signaling in atherosclerotic calcification. Circ Res (2011); 108: 1482-1493.
25. Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, Klutmann S. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med (2010); 51: 862-865.
26. Derlin T, Wisotzki C, Richter U, Apostolova I, Bannas P, Weber C, Mester J, Klutmann S. In vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factors. J Nucl Med (2011); 52: 362-368.
27. Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ, Detrano RC, Dunstan CR, Shah PK, Rajavashisth TB. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA (2003); 100: 11201-11206.
28. Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol (2012); 59: 1539-1548.
29. Dweck MR, Khaw HJ, Sng GK, Luo EL, Baird A, Williams MC, Makiello P, Mirsadraee S, Joshi NV, van Beek EJ, Boon NA, Rudd JH, Newby DE. Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur Heart J (2013); 34: 1567-1574.
30. Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, Tawakol A, Gleeson FV, Lepore JJ, Davis B, Willette RN, Wilkinson IB, Sprecher DL, Cheriyan J. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging (2012); 5: 911-922.
31. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol (2004); 15: 1983-1992.
32. Falk E, Sillesen H, Muntendam P, Fuster V. The high-risk plaque initiative: primary prevention of atherothrombotic events in the asymptomatic population. Curr Atheroscler Rep (2011); 13: 359-366.
33. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011); 378: 1547-1559.
34. Fifer KM, Qadir S, Subramanian S, Vijayakumar J, Figueroa AL, Truong QA, Hoffmann U, Brady TJ, Tawakol A. Positron emission tomography measurement of periodontal (18)f-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammation. J Am Coll Cardiol (2011); 57: 971-976.
35. Figueroa AL, Subramanian SS, Cury RC, Truong QA, Gardecki JA, Tearney GJ, Hoffmann U, Brady TJ, Tawakol A. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging (2012); 5: 69-77.
36. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol (2010); 30: 1282-1292.
37. Fleg JL, Stone GW, Fayad ZA, Granada JF, Hatsukami TS, Kolodgie FD, Ohayon J, Pettigrew R, Sabatine MS, Tearney GJ, Waxman S, Domanski MJ, Srinivas PR, Narula J. Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions. JACC Cardiovasc Imaging (2012); 5: 941-955.
38. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, Di Carli MF, Libby P. Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol (2011); 58: 603-614.
39. Gallagher BM, Ansari A, Atkins H, Casella V, Christman DR, Fowler JS, Ido T, MacGregor RR, Som P, Wan CN, Wolf AP, Kuhl DE, Reivich M. Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med (1977); 18: 990-996.
40. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med (1978); 19: 1154-1161.
41. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart Disease and Stroke Statistics-2013 Update: a Report From the American Heart Association. Circulation (2013); 127: e6-e245.
42. Graebe M, Pedersen SF, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg (2009); 37: 714-721.
43. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006); 6: 508-519.
44. Hobson RW, Mackey WC, Ascher E, Murad MH, Calligaro KD, Comerota AJ, Montori VM, Eskandari MK, Massop DW, Bush RL, Lal BK, Perler BA. Management of atherosclerotic carotid artery disease: clinical practice guidelines of the Society for Vascular Surgery. J Vasc Surg (2008); 48: 480-486.
45. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res (1995); 77: 1129-1135.
46. Ido T, Wan CN, Casella V, Fowler JS, Wolf AP. Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose. J Labelled Compd Radiopharm (1978); 14: 175-183.
47. Ishii H, Nishio M, Takahashi H, Aoyama T, Tanaka M, Toriyama T, Tamaki T, Yoshikawa D, Hayashi M, Amano T, Matsubara T, Murohara T. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clin Ther (2010); 32: 2337-2347.
48. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis (1986); 6: 131-138.
49. Joshi FR, Lindsay AC, Obaid DR, Falk E, Rudd JH. Non-invasive imaging of atherosclerosis. Eur Heart J Cardiovasc Imaging (2012); 13: 205-218.
50. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ. Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer (2008); 112: 2447-2455.
51. Kim EJ, Yong HS, Seo HS, Lim SY, Kim SW, Kim MN, Kim YK, Poddar KL, Ramasamy S, Na JO, Choi CU, Lim HE, Kim JW, Kim SH, Lee EM, Rha SW, Park CG, Oh DJ. Association between aortic calcification and stable obstructive coronary artery disease. Int J Cardiol (2011); 153: 192-195.
52. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, Smialek J, Virmani R. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol (2000); 157: 1259-1268.
53. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood (1994); 84: 1415-1420.
54. Kovacic JC, Fuster V. Smoking gun theory: angiographically normal or mild coronary plaque as a cause of myocardial infarction. Circulation (2012); 126: 2918-2920.
55. Levin KT, Hogild KS, Vinter OO, Aznar M, Andersen FL. Innovations in PET/CT. Q J Nucl Med Mol Imaging (2012); 56: 268-279.
56. Li X, Samnick S, Lapa C, Israel I, Buck AK, Kreissl MC, Bauer W. 68 Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors. EJNMMI Res (2012); 2: 52.
57. Libby P. Inflammation in atherosclerosis. Nature (2002); 420: 868-874.
58. Moses WW. Fundamental Limits of Spatial Resolution in PET. Nucl Instrum Methods Phys Res A (2011); 648(Suppl. 1): S236-S240.
59. Motoyama S, Kondo T, Sarai M, Sugiura A, Harigaya H, Sato T, Inoue K, Okumura M, Ishii J, Anno H, Virmani R, Ozaki Y, Hishida H, Narula J. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol (2007); 50: 319-326.
60. Muntendam P, McCall C, Sanz J, Falk E, Fuster V. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease-study design and objectives. Am Heart J (2010); 160: 49-57.
61. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003a); 108: 1772-1778.
62. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003b); 108: 1664-1672.
63. Owen DR, Lindsay AC, Choudhury RP, Fayad ZA. Imaging of atherosclerosis. Annu Rev Med (2011); 62: 25-40.
64. Oxboel J, Schjoeth-Eskesen C, El-Ali HH, Madsen J, Kjaer A. (64)Cu-NODAGA-c(RGDyK) Is a Promising New Angiogenesis PET Tracer: correlation between Tumor Uptake and Integrin alpha(V)beta(3) Expression in Human Neuroendocrine Tumor Xenografts. Int J Mol Imaging (2012); 2012: 379807.
65. Panin VY, Kehren F, Michel C, Casey M. Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging (2006); 25: 907-921.
66. Pedersen SF, Graebe M, Fisker Hag AM, Hojgaard L, Sillesen H, Kjaer A. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun (2010); 31: 423-429.
67. Pedersen SF, Graebe M, Hag AM, Hoejgaard L, Sillesen H, Kjaer A. Microvessel Density But Not Neoangiogenesis Is Associated with (18)F-FDG Uptake in Human Atherosclerotic Carotid Plaques. Mol Imaging Biol (2012); 14: 384-392.
68. Pedersen SF, Graebe M, Hag AM, Hoejgaard L, Sillesen H, Kjaer A. Microvessel density but not neoangiogenesis is associated with 18F-FDG uptake in human atherosclerotic carotid plaques. Mol Imaging Biol (2012); 14: 384-392.
69. 18F-FDG imaging of human atherosclerotic carotid plaques reflects gene expression of the key hypoxia marker HIF-1a. Am J Nucl Med Mol Imaging (2013); 3: 384-392.
70. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med (1975); 16: 210-224.
71. Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. 68 Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol (2012); 39: 777-784.
72. Polycarpou I, Thielemans K, Manjeshwar R, Aguiar P, Marsden PK, Tsoumpas C. Comparative evaluation of scatter correction in 3D PET using different scatter-level approximations. Ann Nucl Med (2011); 25: 643-649.
73. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab (2006); 4: 211-221.
74. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Gallagher B, Hoffman E, Alavi A, Sokoloff L. Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-d-glucose. Acta Neurol Scand Suppl (1977); 64: 190-191.
75. Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis-a double-edged sword. Ann Med (2008); 40: 606-621.
76. Ripa RS, Knudsen A, Hag AM, Lebech AM, Loft A, Keller SH, Hansen AE, von Benzon E, Hojgaard L, Kjaer A. Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. Am J Nucl Med Mol Imaging (2013); 3: 361-371.
77. Rominger A, Saam T, Vogl E, Ubleis C, la Fougère C, Forster S, Haug A, Cumming P, Reiser MF, Nikolaou K, Bartenstein P, Hacker M. In vivo imaging of macrophage activity in the coronary arteries using 68 Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med (2010); 51: 193-197.
78. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med (1999); 340: 115-126.
79. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation (2002); 105: 2708-2711.
80. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, Fuster V, Fayad ZA. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol (2007); 50: 892-896.
81. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, Rafique A, Hargeaves R, Farkouh M, Fuster V, Fayad ZA. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med (2008); 49: 871-878.
82. Rudd JH, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, Farkouh ME, Fayad ZA. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009); 2: 107-115.
83. Schlemmer HP, Pichler BJ, Schmand M, Burbar Z, Michel C, Ladebeck R, Jattke K, Townsend D, Nahmias C, Jacob PK, Heiss WD, Claussen CD. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology (2008); 248: 1028-1035.
84. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics (1999); 19: 61-77.
85. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnens AP. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol (2008); 51: 1258-1265.
86. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med (2007); 48: 932-945.
87. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol (2006); 48: 1825-1831.
88. Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, Sadato N, Sugimoto K, Itoh H. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med (2000); 14: 323-328.
89. Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology (2003); 229: 831-837.
90. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol (2006); 48: 1818-1824.
91. Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology (1975); 114: 89-98.
92. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med (1992); 33: 2133-2137.
93. Vallabhajosula S, Fuster V. Atherosclerosis: imaging techniques and the evolving role of nuclear medicine. J Nucl Med (1997); 38: 1788-1796.
94. Van de Wiele C, Lahorte C, Vermeersch H, Loose D, Mervillie K, Steinmetz ND, Vanderheyden JL, Cuvelier CA, Slegers G, Dierck RA. Quantitative tumor apoptosis imaging using technetium-99 m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol (2003); 21: 3483-3487.
95. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol (2005); 25: 2054-2061.
96. Vita JA. Endothelial function. Circulation (2011); 124: e906-e912.
97. Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology (2006); 238: 405-422.
98. Warburg O, Posener E, Negelein E. Über den stoffwechesel der Carcinomzelle. Biochem Z (1924); 152: 309-344.
99. Wasselius J, Larsson S, Jacobsson H. Time-to-time correlation of high-risk atherosclerotic lesions identified with [(18)F]-FDG-PET/CT. Ann Nucl Med (2009a); 23: 59-64.
100. Wasselius J, Larsson S, Sundin A, Jacobsson H. Assessment of inactive, active and mixed atherosclerotic plaques by 18F-FDG-PET; an age group-based correlation with cardiovascular risk factors. Int J Cardiovasc Imaging (2009b); 25: 133-140.
101. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest (1994); 93: 2106-2113.
102. WHO. World Health Statistics 2012, pp. 33-85 (2012). World Health Organization. Ref Type: Online Source.
103. Wu YW, Kao HL, Huang CL, Chen MF, Lin LY, Wang YC, Lin YH, Lin HJ, Tzen KY, Yen RF, Chi YC, Huang PJ, Yang WS. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging (2012); 39: 399-407.
104. Yan J, Stringer SE, Hamilton A, Charlton-Menys V, Gotting C, Muller B, Aeschlimann D, Alexander MY. Decorin GAG synthesis and TGF-beta signaling mediate Ox-LDL-induced mineralization of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2011); 31: 608-615.
105. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med (2001); 26: 314-319.